DCTH - Delcath Systems, Inc.

Delcath Systems develops and commercializes the HEPZATO KIT, a drug-device combination that delivers melphalan chemotherapy directly into the liver via hepatic arterial infusion (HAI), FDA-approved in 2023 for metastatic uveal melanoma with liver involvement; the same technology is sold in Europe as CHEMOSAT under CE mark. The business model is a specialty oncology capital/consumables model, selling the percutaneous hepatic perfusion system and single-use drug kits to interventional oncologists and cancer centers on a per-procedure basis. Revenue is sub-$50M and growing from a near-zero commercial baseline post-FDA approval, with the US as the primary growth market and Europe contributing modest legacy volume. The company remains pre-profitability and cash-consumptive as it builds out its US clinical and commercial infrastructure.

Past Year Trends

• HEPZATO KIT commercial revenue grew from near-zero at launch to an annualized run-rate approaching ~$15–18M by early 2025 as Delcath onboarded qualified treatment centers in the US following the August 2023 FDA approval, though the company remained cash-flow negative throughout the ramp. (Bullish)
• Delcath completed multiple dilutive equity offerings in 2024 totaling approximately $30–40M in gross proceeds to fund the HEPZATO commercial buildout, materially increasing share count and pressuring the stock. (Bearish)
• Delcath expanded its network of certified HEPZATO treatment centers from roughly 15 sites at commercial launch to approximately 40–50 qualified US centers by mid-2025, broadening patient access for uveal melanoma liver metastases. (Bullish)

Next Year Trends

• Readout from the ALIGN trial evaluating HEPZATO in colorectal cancer liver metastases—a market orders of magnitude larger than uveal melanoma—represents the single largest binary catalyst; positive data could support a supplemental NDA submission and a material re-rating of the addressable market. (Bullish)
• Ongoing Medicare/CMS and private-payer coverage determinations for HEPZATO reimbursement remain a critical gating factor; failure to secure broad coverage at adequate reimbursement rates would constrain revenue per procedure and slow center adoption regardless of clinical demand. (Bearish)
• European CHEMOSAT revenues through Delcath's distribution partnerships face pricing pressure from national health technology assessments in key markets including Germany and the UK, limiting the contribution from the ex-US business as a near-term revenue offset. (Bearish)

Red Flags

[Securities Fraud / Investigation] Securities fraud class action lawsuit filed against Delcath Systems circa 2013 by Pomerantz LLP and others, alleging the company made false and misleading statements regarding the safety and efficacy of its CHEMOSAT hepatic delivery system device to inflate the stock price. — Pomerantz LLP class action filing, 2013

[Financial Restatement / Auditor Issue] Delcath Systems' independent auditors issued a going concern opinion in annual filings, citing recurring net losses and uncertainty about the company's ability to continue as a going concern without additional financing. — Delcath Systems Annual Report (10-K), auditor opinion, Multiple years through at least 2023

[Exchange Delisting Warning] NASDAQ issued a deficiency notice to Delcath Systems for failure to maintain the minimum bid price requirement under Listing Rule 5550(a)(2), requiring the company to regain compliance or face delisting. — NASDAQ Listing Qualifications / Delcath Systems SEC 8-K disclosure, 2022-2023